Ocular Immunology and Inflammation最新文献

{"title":"Letter to Editor: Comment on Ioanna Tsioti et al. \"Systemic Lipopolysaccharide Exposure Exacerbates Choroidal Neovascularization in Mice\".","authors":"Gokul Sudhakaran","doi":"10.1080/09273948.2024.2377736","DOIUrl":"10.1080/09273948.2024.2377736","url":null,"abstract":"<p><p>This study by Ioanna Tsioti and colleagues delves into the exacerbation of choroidal neovascularization (CNV) through systemic exposure to lipopolysaccharide (LPS) in a mouse model. The research highlights the molecular and cellular mechanisms by which systemic inflammation can influence ocular conditions, particularly in the context of age-related macular degeneration (AMD). Utilizing a combination of in vivo fluorescein angiography, in situ hybridization, and flow cytometry, the study provides critical insights into the dynamic interaction between systemic inflammatory stimuli and CNV progression. Key findings include increased infiltration of monocyte-derived macrophages and enhanced Vegfα mRNA expression in Glul-expressing cells following systemic LPS exposure. These results suggest potential therapeutic targets for mitigating CNV associated with systemic inflammatory responses.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2616-2617"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Maghsoudlou et al. Titled \"Uveitis Associated with Monogenic Autoinflammatory Syndromes in Children\".","authors":"Gokul Sudhakaran","doi":"10.1080/09273948.2024.2382345","DOIUrl":"10.1080/09273948.2024.2382345","url":null,"abstract":"<p><p>The work by Maghsoudlou et al. provides a comprehensive examination of monogenic autoinflammatory syndromes (MAIS) in children, with a specific focus on uveitis as a significant clinical manifestation. It meticulously details the genetic underpinnings, clinical features, diagnostic criteria, and current therapeutic strategies, including the use of biologics. This critique highlights the strengths of the review and suggests further exploration in areas such as long-term treatment outcomes, genotype-phenotype correlations, and the impact of MAIS on quality of life. Future research could benefit from longitudinal studies and enhanced predictive models to improve management and treatment personalization.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2618-2619"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Effect of Different Treatment Doses of Intrastromal Vancomycin in a Rabbit Model of Methicillin-Resistant Staphylococcus Aureus (MRSA) Keratitis.","authors":"Abdullah Bayrak, Serdal Çelebi, Fatma Avcıoğlu, Yunus Alkan","doi":"10.1080/09273948.2024.2382928","DOIUrl":"10.1080/09273948.2024.2382928","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effect of different doses of vancomycin on a rabbit model of MRSA keratitis.</p><p><strong>Methods: </strong>Twenty-four eyes of 24 New-Zealand White rabbits were included in the study. MRSA keratitis was applied to 24 left eyes of 24 New Zealand rabbits. Twenty-four hours after MRSA inoculation; 0.5 mg/0.1 mL, 1 mg/0.1 mL, and 2 mg/0.1 mL and balanced salt solution were administered to 6 rabbits in 4 groups, respectively.</p><p><strong>Results: </strong>The effect of different doses of vancomycin on reducing bacterial load was found to be statistically significant when each was compared to the control group (<i>p</i> = 0.006). When comparing the dosages with each other, no superiority was shown (<i>p</i> = 0.297, <i>p</i> = 0.749, <i>p</i> = 0.262 respectively). There was a significant increase in the posttreatment total clinical score in the control and 2 mg/0.1 mL groups compared to the pretreatment score (<i>p</i> = 0.001, <i>p</i> = 0.001 respectively).</p><p><strong>Conclusion: </strong>It is emphasized that necessary treatment can be achieved by administering less antibiotic (0.5 mg/0.1 mL) to the corneal intrastromal area.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2405-2410"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors Reply to Letter to the Editor - In Response to: Comment on Bocanegra-Oyola et al.'s \"Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis\".","authors":"Carlos Cifuentes-González, Natalia Bocanegra-Oyola, Alejandra de-la-Torre","doi":"10.1080/09273948.2024.2408649","DOIUrl":"10.1080/09273948.2024.2408649","url":null,"abstract":"<p><p>In response to Dr. Kasperkiewicz's commentary on our meta-analysis conducted by Bocanegra-Oyola et al., we fully agree with refining diagnostic processes for ocular pemphigoid, particularly in differentiating it from pseudopemphigoid. We concur that relying solely on clinical findings may result in misdiagnoses. Confirming the diagnosis via biopsy can be challenging, requiring multiple biopsies in some patients, and should always be supported by a multidisciplinary clinical assessment involving ophthalmologists and dermatologists.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2624-2625"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Causal Relationship Between Gut Microbiota and Allergic Conjunctivitis: A Two-Sample Mendelian Randomization Study.","authors":"Yuanyang Huang, Shu Wang, Jinfang Huang, Yining Shen, Leilei Zou, Hong Liu","doi":"10.1080/09273948.2024.2388202","DOIUrl":"10.1080/09273948.2024.2388202","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the causal association between gut microbiota and allergic conjunctivitis.</p><p><strong>Methods: </strong>A two-sample Mendelian randomization (MR) analysis was performed using the summary statistics of gut microbiota (18,340) from MiBio-Gen consortium and allergic conjunctivitis data (<i>n</i> = 218,792) obtained from the IEU Open GWAS project. F-statistics and sensitivity analyses were used to address potential biases and ensure the reliability of our findings. Reverse MR analysis was conducted to assess the possible of reverse causal relationships.</p><p><strong>Results: </strong>The inverse variance weighted estimates revealed the protective potential of the phylum Euryarchaeota against allergic conjunctivitis (OR = 0.87, <i>p</i> = 6.17 × 10^-4). On the other hand, the genus Christensenellaceae R.7 group (OR = 0.75, <i>p</i> = 2.89 × 10^-3), family Peptostreptococcaceae (OR = 0.83, <i>p</i> = 6.22 × 10^-3), genus Lachnospiraceae FCS020 group (OR = 0.82, <i>p</i> = 0.02) all showed a suggestive protective association with allergic conjunctivitis. Additionally, sensitivity analysis confirmed the robustness of the above associations. In the reverse MR analysis, no significant causal association was found between gut microbiota and allergic conjunctivitis.</p><p><strong>Conclusion: </strong>This study has revealed a potential causal correlation between the phylum Euryarchaeota and allergic conjunctivitis, offering new insights to improve prevention and treatment of this condition.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2411-2420"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Spectrum of Papillophlebitis.","authors":"Sara Abdel Jalil, Radgonde Amer","doi":"10.1080/09273948.2024.2359622","DOIUrl":"10.1080/09273948.2024.2359622","url":null,"abstract":"<p><strong>Purpose: </strong>Papillophlebitis is a rare condition, manifesting as CRVO in the young adults. We aim to present our experience in managing patients with papillophlebitis.</p><p><strong>Methods: </strong>Retrospective review of patients' medical files.</p><p><strong>Results: </strong>Included were seven patients with a mean presenting age of 24.86 ± 4.4 years and mean follow-up of 40.4 ± 50.5 months. No pre-existing systemic illness was reported by any patient. One patient was subsequently diagnosed to have Behçet disease and another patient was diagnosed with homozygous mutation to MTHFR C6771. On presentation, fluorescein angiograms showed diffuse vascular and optic disc leakage. Four patients presented with papillophlebitis-associated CME, for which they were treated with systemic steroids and intravitreal anti-VEGF injections. One patient showed full recovery. In 3 patients, due to the protracted course of papillophlebitis and refractory CME, adalimumab was added. All 3 patients eventually showed complete resolution of CME. Two of them eventually developed extensive peripheral capillary non-perfusion that was treated with panretinal photocoagulation. Three patients did not develop CME: In two patients, papillophlebitis resolved after a short course of prednisone while in the third patient, papillophlebitis resolved spontaneously. Mean ± SD presenting log MAR VA was 0.2 ± 0.32 and it was 0.057 ± 0.11 at the last follow-up.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is the first description that suggests a role for TNF-ɑ blockers in the management of patients with recalcitrant papillophlebitis and non-responsive CME. Further studies are needed in order to thoroughly investigate the molecular background of papillophlebitis and clinical outcomes associated with this class of medications.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"2515-2520"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to Adherence with Immunosuppressive Therapy in Patients with Uveitis.","authors":"Karen Sun, Rayna Marshall, Michael Frankland, Amal Taylor, Cynthia Montana, Eric Crowell, Karen R Armbrust, Laura Kopplin, Meghan Berkenstock","doi":"10.1080/09273948.2024.2430709","DOIUrl":"https://doi.org/10.1080/09273948.2024.2430709","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the barriers to adherence with immunomodulatory therapy (IMT) for patients with uveitis across multiple regions of the United States.</p><p><strong>Methods: </strong>A multi-center survey of adult and pediatric patients with ocular inflammatory diseases undergoing treatment with IMT was conducted between September 2021 and August 2022. Participating sites included Johns Hopkins Wilmer Eye Institute, Wong Eye Institute of the University of Texas at Austin, University of Wisconsin-Madison, University of Minnesota, Veterans Affairs Hospital of Minneapolis, and Washington University of St. Louis. Each patient completed a self-reporting survey to identify barriers to adherence.</p><p><strong>Results: </strong>The survey was completed by 98 subjects, of whom were 71% white, 67% female, and 61% had a college or advanced degree. Nearly half (49%) were on two or more IMTs of which the most common were methotrexate (38%), mycophenolate (36%), or adalimumab (36%). Nearly half (52%) of patients required reminders to take their medications and 20% found it difficult to take IMT regularly, with 12% struggling to take medications multiple times a day. A lack of refills resulted in 15% of patients missing doses. Limitations to completing laboratory studies to monitor for drug-related side-effects included finding time (10%) and cost (22%).</p><p><strong>Conclusion: </strong>Barriers to IMT treatment include laboratory study cost, difficulty with medication administration, and adhering to medication schedules. Monthly cost of medication was high for some, but no patients were unable to take IMT due to insurance loss. Addressing these barriers may improve IMT adherence for uveitis patients and better clinical outcomes.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Medical Therapy Failure in Microbial Keratitis: Risk Factors and Management Alternatives.","authors":"David Lamas-Francis, Daniel Navarro, Raquel Mansilla, Victoria de-Rojas, Claudio Moreno, Enrique Dios, Jesús Rigueiro, Dolores Álvarez, Paloma Crego, Teresa Rodríguez-Ares, Rosario Touriño","doi":"10.1080/09273948.2024.2433171","DOIUrl":"https://doi.org/10.1080/09273948.2024.2433171","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the treatments used in cases of infectious keratitis and determine the risk factors associated with treatment failure, including prolonged infection duration, treatment modifications, and the need for surgical intervention.</p><p><strong>Patients and methods: </strong>This retrospective case series includes culture-proven microbial keratitis cases treated in nine hospitals in the region of Galicia, Spain, between 2010 and 2020.</p><p><strong>Results: </strong>A total of 654 patients were included. Prolonged infection duration was associated with factors such as advanced age, deep infiltrates, corneal thinning, and large epithelial defects. Initial empirical treatment was modified in 204 cases (31.2%), with 113 cases requiring changes due to antibiotic resistance and 88 cases due to clinical deterioration. Polymicrobial infections, contact with vegetable matter, previous herpetic keratitis, and topical steroid use were identified as risk factors for treatment modification. Surgical intervention was required in 142 cases (21.7%). Among these, 50 patients (7.6%) underwent evisceration, 43 (6.6%) received amniotic membrane transplantation, and 37 (5.7%) underwent tectonic penetrating keratoplasty. Previous keratoplasty, prior herpetic keratitis, topical steroid use, and large epithelial defects were also significant risk factors for surgical intervention.</p><p><strong>Conclusions: </strong>Treatment failure in cases of microbial keratitis (MK) may be influenced by systemic factors, such as advanced age, and ocular factors, including large epithelial defects, deep infiltrates, polymicrobial infections, contact with vegetable matter, and previous topical steroid use. Identifying these risk factors is essential for guiding empirical treatment and recognizing refractory ulcers that may require more intensive management, including surgical intervention.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication Refill Adherence in Patients with Chronic Inflammatory Eye Disease.","authors":"Arthi D Bharadwaj, Avisek Datta, Pooja Bhat, Ann-Marie Lobo-Chan","doi":"10.1080/09273948.2024.2427257","DOIUrl":"https://doi.org/10.1080/09273948.2024.2427257","url":null,"abstract":"<p><strong>Purpose: </strong>To utilize pharmacy dispenses to investigate adherence rates to immunosuppressive therapy (IMT) for the treatment of noninfectious inflammatory eye disease (IED), impact of adherence on disease control, factors associated with nonadherence, and association between adherence in the medical record and pharmacy dispenses.</p><p><strong>Method: </strong>Retrospective medical chart review was conducted on patients followed for at least 2 years in the uveitis clinic. Appointment and lab attendance, and provider documentation, determined adherence through the medical record. Dispense history was obtained from pharmacies, and IMT infusion dates were noted. Disease control was determined by clinical exam findings.</p><p><strong>Results: </strong>Sixty-three patients qualified for the study. The mean age was 49 years (SD = 19.4), 76.2% were female, 36.5% were Black/African American, and 96.8% were taking 1 or 2 IMTs. Pharmacy refill data was collected from 58 patients to determine an adherence rate (AR) of 63.9%. Thirty-nine patients (67.2%) had an average AR < 85% by pharmacy refill data and were thus deemed nonadherent. The majority of patients (86.2%) achieved ocular inflammation control. Nonadherence was 4.72 times more likely in patients taking >1 medication compared to one medication alone (95% CI: 1.02-21.86, <i>p</i> = 0.047). Comparing adherence from information in the medical record to pharmacy refill data, 71.6% of IMT comparisons were congruent (<i>p</i> < 0.0001).</p><p><strong>Conclusion: </strong>Patients taking IMT for >2 years demonstrated an AR < 65% based on pharmacy data. Most patients achieved ocular quiescence. Using pharmacy information as an objective measure of adherence correlates with assessing adherence through medical record information.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":2.6,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D Supplementation and Remission from Chronic Anterior Uveitis.","authors":"Hueyjong Shih, Yineng Chen, Katie Huynh, Eric B Suhler, Jennifer E Thorne, Nirali P Bhatt, C Stephen Foster, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt, James T Rosenbaum, H Nida Sen, Sapna S Gangaputra, Abhishek R Payal, Hosne Begum, Naira Khachatryan, Sherri-Ann M Burnett-Bowie, Gui-Shuang Ying, John H Kempen, Lucia Sobrin","doi":"10.1080/09273948.2024.2427857","DOIUrl":"https://doi.org/10.1080/09273948.2024.2427857","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic anterior uveitis (CAU) often requires suppressive therapy, which has potential side effects including cataract, ocular hypertension, and increased risk of infection. No remittive therapy is currently available; however, several studies have demonstrated an association between low 25-hydroxy Vitamin D (25OHD) levels and either uveitis incidence or uveitis disease activity. This study investigates the potential of Vitamin D supplementation as a remittive treatment for CAU.</p><p><strong>Methods: </strong>We conducted a retrospective analysis using data from the Systemic Immunosuppressive Therapy for Eye Disease (SITE) cohort study, which included patients with ocular inflammatory disease seen at U.S. tertiary centers between 1979 and 2010. Vitamin D supplementation data was analyzed for patients with CAU. Eyes were considered in remission if they remained quiet for at least 90 days off all anti-inflammatory treatment for eye disease.</p><p><strong>Results: </strong>Among 2688 patients who never used Vitamin D, the cumulative adjusted CAU remission incidence was 13.5% at the 16-month follow-up. In contrast, among 75 patients who used Vitamin D for a duration of ≤1 year, the cumulative adjusted CAU remission incidence was 28% at 16 months. The use of Vitamin D was associated with a crude hazard ratio for remission of 2.14 [95% confidence interval (CI) 1.23-3.71, <i>p</i> = 0.0071], and an adjusted hazard ratio for remission of 2.43 [95% CI: 1.36-4.33, <i>p</i> = 0.0027].</p><p><strong>Conclusion: </strong>In the SITE Cohort, Vitamin D supplementation is associated with a significantly increased incidence of remission. Vitamin D supplementation should be explored in a prospective trial as the next step of evaluation.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":2.6,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}